Etripamil is a small molecule commercialized by Milestone Pharmaceuticals, with a leading Pre-Registration program in Supraventricular Tachycardia. According to Globaldata, it is involved in 12 clinical trials, of which 8 were completed, 3 are ongoing, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Etripamil’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for Etripamil is expected to reach an annual total of $488 mn by 2035 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Etripamil Overview
Etripamil (MSP-2017) is under development for the treatment of transient cardiovascular conditions such as paroxysmal supraventricular tachycardia (PSVT), and atrial fibrillation. The drug candidate is a short-acting therapeutic administered by intranasal route as a spray. It is a new chemical entity and acts by targeting calcium channel.
It was under development for stable angina.
Milestone Pharmaceuticals Overview
Milestone Pharmaceuticals is a Pharmaceutical company. It develops novel small molecule therapeutics. The company undertakes the development of small molecule therapeutics based on clinically validated mechanisms, for the treatment of cardiovascular diseases. It’s lead product etripamil, is a potent short-acting calcium channel antagonist for the systemic treatment of cardiovascular conditions such as angina, paroxysmal supraventricular tachycardia and atrial arrhythmias. It offers products through nasal sprays for the provision of rapid systemic drug delivery that can be used by electrocardiogram (ECG)-diagnosed patient. It operates in the US and Canada. Milestone Pharmaceuticals is headquartered in Saint-Laurent, Quebec, Canada.
The company reported revenues of (US Dollars) US$5 million for the fiscal year ended December 2022 (FY2022), a decrease of 66.7% over FY2021. The operating loss of the company was US$59.6 million in FY2022, compared to an operating loss of US$43.1 million in FY2021. The net loss of the company was US$58.4 million in FY2022, compared to a net loss of US$42.9 million in FY2021.
For a complete picture of Etripamil’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
